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Abstract
Background and Objective Enthusiasm for the use of outcomes-based managed entry agreements (OBMEAs) to manage 
uncertainties apparent at the time of appraisal/pricing and reimbursement of new medicines has waned over the past decade, 
as challenges in establishment, implementation and re-appraisal have been identified. With the recent advent of innovative 
treatments for rare diseases that have uncertainties in the clinical evidence base, but which could meet a high unmet need, 
there has been renewed interest in the potential of OBMEAs. The objective of this research was to review the implementation 
of OBMEAs for two case studies across countries in the European Union, Australia and Canada, to identify good practices 
that could inform development of tools to support implementation of OBMEAs.
Methods To investigate how OBMEAs are being implemented with rare disease treatments, we collected information from 
health technology assessment/payer experts in countries that had implemented OBMEAs for either nusinersen in spinal mus-
cular atrophy or tisagenlecleucel in two cancer indications. Operational characteristics of the OBMEAs that were publicly 
available were documented. Then, the experts discussed issues in implementing these OBMEAs and specific approaches 
taken to overcome challenges.
Results The OBMEAs identified were based on individual outcomes to ensure appropriate use, manage continuation of treat-
ment and in two cases linked to payment schedules, or they were population based, coverage with evidence development. 
For nusinersen, population-based OBMEAs are documented in Belgium, England and the Netherlands and individual-based 
schemes in Bulgaria, Ireland, Italy and Lithuania. For tisagenlecleucel, there were population-based schemes in Australia, 
Belgium, England and France and individual-based schemes in Italy and Spain. Comparison of the OBMEA constructs 
showed some clear published frameworks and clarity of the uncertainties to be addressed that were similar across coun-
tries. Agreements were generally made between the marketing authorisation holder and the payer with involvement of 
expert physicians. Only England and the Netherlands involved patients. Italy used its long-established, national, web-based, 
treatment-specific data collection system linked to reimbursement and Spain has just developed such a national treatment 
registry system. Other countries relied on a variety of data collection systems (including clinical registries) and administra-
tive data. Durations of agreements varied for these treatments as did processes for interim reporting. The processes to ensure 
data quality, completeness and sufficiency for re-analysis after coverage with evidence development were not always clear, 
neither were analysis plans.
Conclusions These case studies have shown that important information about the constructs of OBMEAs for rare disease 
treatments are publicly available, and for some jurisdictions, interim reports of progress. Outcomes-based managed entry 
agreements can play an important role not only in reimbursement, but also in treatment optimisation. However, they are 
complex to implement and should be the exception and not the rule. More recent OBMEAs have developed document cov-
enants among stakeholders or electronic systems to provide assurances about data sufficiency. For coverage with evidence 
development, there is an opportunity for greater collaboration among jurisdictions to share processes, develop common data 
collection agreements, and share interim and final reports. The establishment of an international public portal to host such 
reports would be particularly valuable for rare disease treatments.
Extended author information available on the last page of the article
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Key Points for Decision Makers 
Outcomes-based managed entry agreements can in 
some circumstances help resolve uncertainties relating 
to the value and optimal use of a rare disease treatment, 
but they should be supported by a covenant agreed by 
all stakeholders providing assurance that all necessary 
actions will be taken to ensure that the data collected 
will be sufficient for decision making.
When used, outcomes-based managed entry agreement 
constructs for data collection and reports of clinical 
results should be published and shared to enable agree-
ment of core data across jurisdictions, data aggregation 
and to support health system learnings.
An international public repository for outcomes-based 
managed entry agreement reports akin to the HTA data-
base hosted by the International Network of Agencies for 
Health Technology Assessment would be valuable.
1  Background
Because of the difficulties associated with clinical research 
in rare diseases, treatments often come to market with a 
small evidence base involving uncontrolled or small ran-
domised controlled trials of short duration, studying out-
comes that may not clearly demonstrate patient benefit [1]. 
This leads to a range of uncertainties relating to the popula-
tion appropriate for reimbursement, and to the determina-
tion of clinical and cost effectiveness. Alongside this, rare 
disease treatments are often associated with high prices, 
which challenge standard willingness-to-pay thresholds 
and raise concerns about budget impact, even after negotia-
tion of financial/commercial agreements. Some countries 
have special appraisal and reimbursement mechanisms that 
allow flexibility in evaluation of rare disease treatments [2], 
such as leniency in critical assessment/review of evidence, 
flexibility in base-case assumptions for economic modelling 
and broader consideration of value. Despite these adapted 
approaches, some treatments for which substantial clinical 
benefit or large gains in quality-adjusted life-years are esti-
mated are still associated with major uncertainties, which 
means they cannot be recommended for use or full reim-
bursement in a health system. Alongside this, the high unmet 
need, childhood onset and severity of many rare diseases 
means there is often strong clinical, patient/parent and politi-
cal lobbying to provide access to such rare disease treat-
ments. In these situations, one solution to access could be 
an outcomes-based managed entry agreement (OBMEA)1 
that seeks to manage the clinical and financial uncertainties 
[3, 4].
Outcomes-based managed entry agreements can be used 
with any form of health technology and occur at two levels 
for a range of purposes including resolution of uncertain-
ties in clinical evidence, management of budget impact, and 
improved understanding of real-life and long-term effective-
ness to optimise care:
Individual: ensuring only eligible patients receive 
treatment, sometimes with assessment of outcomes 
to determine treatment continuation (appropriate 
use) or linked to payment schemes (paying only 
if response achieved or refund if response not 
achieved)
Population: using coverage with evidence devel-
opment (CED)/post-licensing evidence generation 
as a conditional coverage mechanism post-health 
technology assessment (HTA)/reimbursement that 
requires evidence collection to inform re-appraisal 
or pricing and reimbursement re-negotiations
However, even with prevalent conditions, implemen-
tation of OBMEAs has been found to be challenging [5, 
6] owing to administrative burdens on health providers/
payers and for population-based schemes, the insuffi-
ciency of data to inform re-appraisal and funding of data 
collection [7]. Pricing and reimbursement processes are 
the responsibility of the Ministry of Health nationally 
and/or a payer, which may have a “jurisdiction” that is 
national, relates to a region in the country or to a pop-
ulation covered by the health plan. Furthermore, these 
OBMEAs must be agreed alongside confidential commer-
cial arrangements, thus the constructs of the OBMEAs are 
often kept confidential or published in local languages 
that have made sharing difficult. As a consequence, dif-
ferent agreements arise for the same treatment in different 
jurisdictions. This represents a challenge for the market-
ing authorisation holder (company/health technology 
sponsor), but for rare diseases this is also an important 
inefficiency as sharing of outcomes data across jurisdic-
tions could create more robust evidence for re-appraisal 
[8, 9].
Work Package (WP) 10 of the European Commission-
funded H2020 IMPACT HTA project has undertaken 
research to develop an appraisal framework suitable for rare 
disease treatments that includes consideration of when and 
how to implement OBMEAs. For this, IMPACT HTA WP10 
drew on the European Commission-funded H2020 COMED 
1 Including performance-based risk sharing schemes/agreements and 
coverage/post-licensing/access with evidence/data development/gen-
eration/collection.
OBMEA for Nusinersen and Tisagenlecleucel
project. The COMED systematic review of CED schemes 
[10] identified a range of challenges, many of which seemed 
transferable to rare disease treatments. We categorised these 
into issues relating to:
• Establishment (including purpose, stakeholder responsi-
bilities, agreement on eligibility and continuation crite-
ria, outcomes to be studied)
• Implementation (including research protocol, data col-
lection infrastructure, monitoring to improve data qual-
ity and completeness, amendment processes, feedback 
mechanisms for physicians and patients, resourcing, ethi-
cal issues)
• Re-appraisal (including ability to implement a revised 
reimbursement decision).
Reckers-Droog et al. [10] suggested that future research 
should seek to deepen understanding of the challenges of 
OBMEAs for different health technologies and consider 
impacts for all stakeholders including clinicians and patients. 
Hence, IMPACT HTA WP10 organised workshops with all 
stakeholders involved in National Institute for Health and 
Care Excellence (NICE) Highly Specialised Technologies 
(HST) OBMEAs (called managed access agreements). 
These OBMEAs gather data from a variety of health sys-
tem sources for treatments of ultra-rare conditions that are 
provided in a national specialised service in NHS England. 
Then EX undertook a desktop review of the national web-
based registry system of the Italian Medicines Agency, 
AIFA [11]. This in-depth evaluation of all AIFA registries 
over a 15-year period identified 88 registries for rare disease 
indications and explored their form, evolution and impact.
This work from England and Italy showed some differ-
ences in approaches to OBMEAs, but with a commonality 
of issues in relation to clinician (physicians and pharma-
cists) burden of data entry and assessment. As a result, it 
was decided to review the implementation of OBMEAs for 
two specific rare disease treatments across a much broader 
range of countries. The purpose was to explore how different 
health systems had established and implemented both indi-
vidual and population-based OBMEAs and identify good 
practices that could inform development of tools to support 
OBMEAs for rare disease treatments.
2  Methods
Given emerging findings in other parts of IMPACT HTA 
WP10 research, two different treatments designated as 
orphan medicinal products (OMP) by the European Medi-
cines Agency were chosen as case studies: nusinersen and 
tisagenlecleucel. Nusinersen  (Spinraza®) has European 
Union regulatory authorisation for 5q spinal muscular 
atrophy (SMA) and is administered as an intrathecal injec-
tion with four loading doses in the first 2 months and then 
a maintenance dose every 4 months thereafter, continued 
dependent on response. Tisagenlecleucel  (Kymriah®) is a 
one-off CAR-T therapy with European Union regulatory 
authorisation for patients aged up to 25 years with refrac-
tory/relapsed B-cell acute lymphoblastic leukaemia or adults 
with relapsed/refractory diffuse large B-cell lymphoma. 
These provide contrasting cases of: non-cancer vs cancer; 
ongoing vs one-off treatment; babies/adults vs adolescents/
adults; antisense oligonucleotide vs advanced therapeutic 
medicinal products; different HTA/reimbursement routes 
within organisations.
With a good understanding of the processes to undertake 
OBMEAs at NICE and AIFA, a template was developed 
to capture relevant information about OBMEAs in other 
jurisdictions. In February 2020, the template was sent to 
HTA/payer/academic experts in each country in the Euro-
pean Union, European Economic Area, Canada, Australia 
and New Zealand that we had worked with in the docu-
mentation of appraisal processes in another workstream of 
IMPACT HTA WP10. They were asked to complete the tem-
plates using publicly available information. We sent several 
reminder e-mails over the coming months, but this coincided 
with the emergence of the COVID-19 pandemic and thus we 
were sensitive to health system pressures. Therefore, we con-
tacted a market access expert from each marketing authori-
sation holder to identify the countries where their products 
had been reimbursed and those that were likely to have an 
OBMEA and targeted repeated follow-ups to these countries.
The completed templates were reviewed by KF to clarify 
entries and reduce duplication. Each revised table was vali-
dated by the relevant HTA expert. The HTA/payer/academic 
experts (authors) that contributed detailed information were 
invited to two virtual workshops in autumn 2020 to discuss 
their entries in the revised tables, differences in processes, 
new initiatives that had been implemented to overcome 
previous challenges with OBMEAs and the potential for 
future collaboration in relation to OBMEAs for rare disease 
treatments.
3  Results
3.1  Data Returns
3.1.1  Nusinersen
In the data collection phase in summer 2020, it was recog-
nised that the following countries had not authorised/reim-
bursed nusinersen or were unlikely to have an OBMEA: 
Croatia, Denmark, Estonia, Greece, Iceland, Liechtenstein, 
Luxembourg, Malta, New Zealand, Romania and Slovakia 
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and their non-response was not pursued beyond one follow-
up. Canada, Finland, Scotland, Sweden and Switzerland did 
not respond. In Scotland, nusinersen is reimbursed for SMA 
type 1 and from July 2019 it could be prescribed for SMA 
types 2/3 via the new ultra-orphan pathway. This agreement 
lasts for a period of up to 3 years while further evidence on 
effectiveness is generated, but no other details are available2. 
Canada, Sweden and Finland have decentralised systems, 
where the provinces/hospitals/councils negotiate pricing and 
reimbursement and any OBMEA, but these agreements are 
confidential.
For Australia, France, Germany, Hungary, Norway and 
Slovenia, we were informed that nusinersen was reimbursed, 
often with strict inclusion criteria, but without an OBMEA. 
According to the marketing authorisation holder, the Czech 
Republic does have a scheme that assesses effectiveness 
in children after 1 year of treatment and outcomes-based 
continuation criteria are applied, but no further details are 
available.
Templates returned from Austria, Portugal and Spain pro-
vided general responses about OBMEA construction and 
had few details for the specific treatment because the agree-
ments are confidential. Austria made regional reimburse-
ment decisions on nusinersen including for indications and 
any associated OBMEA, but it is known that one region col-
lected motor milestones in the German SMArtCare registry3.
For the remaining countries, templates were returned 
showing CED (population-based) schemes in Belgium, 
England and the Netherlands (Table 1). Responses from 
Bulgaria, Ireland, Italy and Lithuania showed individual-
based OBMEAs used to determine eligibility, continuation 
and, in some cases, total budget caps that are intended to be 
used in pricing and reimbursement renegotiations (Table 2).
An initial response was received from Latvia that docu-
mented an individual-based scheme, but because of health 
system pressures, it has not been possible to validate the data 
summary. In Poland, it is unclear if the scheme proposed 
by the HTA body was implemented. These are shown in 
Table 2 in italic to enable comparisons to the individual-
based schemes that were implemented, and for which there 
is validated information.
3.1.2  Tisagenlecleucel
In the data collection phase, it was determined from 
respondents or the marketing authorisation holder that at 
that point in time, Bulgaria, Estonia, Hungary, Ireland, Lat-
via, Lithuania, Slovakia and Slovenia had not authorised/
reimbursed tisagenlecleucel and that Croatia, Cyprus, Den-
mark, Greece, Iceland, Liechtenstein, Luxembourg, Malta, 
New Zealand and Romania did not have OBMEAs. Con-
tacts in the Czech Republic, Finland and Switzerland did not 
respond. For Portugal, a general response about the process 
was received indicating that any agreement would be made 
with INFARMED and the marketing authorisation holder, 
but that there was a preference for simple discounts.
Norway, Scotland and Sweden had reimbursed tisagen-
lecleucel through standard appraisal and reimbursement 
processes without need for an OBMEA. The Netherlands 
only uses population-based OBMEA for non-cancer OMPs, 
but can establish an individual-based agreement to ensure 
appropriate use. It did not use this for tisagenlecleucel, but 
gave reimbursement for acute lymphoblastic leukaemia only. 
In Poland, there were originally applications for emergency 
access for a limited group of patients, then applications for 
reimbursement were made.
Jørgensen et al. [12] stated that in Germany during the 
initial 12-month free-pricing period, the marketing authori-
sation holder made arrangements with the health insurers, 
covering 60% of the eligible population, for an outcomes-
based rebate for patients who died within a certain period. 
After the early benefit assessment, the reimbursement mech-
anism has reverted to a simple confidential discount.
In Austria, for tisagenlecleucel, there was a national 
agreement on the reimbursed indication agreed by the 
national specialist group of haematologists4 and outcomes 
data are documented in the European Society for Blood 
and Marrow Transplantation. Reimbursement decisions 
(including any OBMEA) were agreed in regions and are 
confidential.
In Canada, CADTH recommended that tisagenlecleu-
cel be provided via interprovincial agreements with clear 
eligibility criteria. It was recommended that standardised 
outcomes data be collected in a pan-Canadian registry to 
generate real-world evidence for consideration in future 
assessments to assess longer term effectiveness, safety and 
cost effectiveness5. No further details are published.
Templates were returned showing CED schemes in Aus-
tralia, Belgium and England and an individual-based scheme 
in Italy. Publications and public reimbursement information 
described CED in France and an individual-based scheme in 
Spain. These are summarised in Table 3.
3.2  Country Comparisons Reimplementing OBMEAs
Every jurisdiction has processes in place to develop com-
mercial agreements/financial Managed Entry Agree-
ments (MEA) within their pricing and reimbursement/
2 Nusinersen (Spinraza) (scottishmedicines.org.uk).
3 https:// www. smart care. de/ en/.
4 https:// www. oegho. at/ filea dmin/ Benut zer/ Aktue lles/ quali taets krite 
rien- car-t- zentr en- final_1. pdf.
5 Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic 
Leukemia and Diffuse Large B-Cell Lymphoma | CADTH.ca.
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commissioning process, many of which have a clear legal 
underpinning. These commercial agreements are highly con-
fidential and generally only involve the marketing authori-
sation holder and the payer/Ministry of Health and for our 
case studies, range from simple discounts to budget caps 
(Belgium, Bulgaria, Latvia [unvalidated], Lithuania, Spain).
Despite the confidentiality of these commercial agree-
ments, public information was available for many jurisdic-
tions to populate our OBMEA templates for the two case 
studies. As shown in Tables 1, 2, and 3, information was 
available about the rationale and design of the OBMEA in 
different countries covering topics that elucidate the pur-
pose of the OBMEA, population given access, duration of 
agreement, stakeholder involvement, data to be collected and 
reporting mechanisms. These elements are presented in the 
following sections with augmentation of intelligence from 
the HTA expert workshops.
3.2.1  Establishing the OBMEA
Some countries have standing committees that oversee the 
establishment of all OBMEAs (such as Belgium) inviting in 
clinical/appraisal experts relevant to the treatment. In Eng-
land, the case studies come from two separate programmes 
within NICE, the Cancer Drugs Fund and the HST pro-
gramme. They had different processes for the establishment 
of OBMEAs, thus the form of data collection agreements is 
slightly different for the case studies (but rationalisation of 
these OBMEA processes is underway for the future).
Outcomes-based managed entry agreements are some-
times limited to specific groups of medicines such as (high-
cost) OMPs or those with conditional or exceptional mar-
keting authorisations, nusinersen was considered via this 
route in The Netherlands. In some countries, OBMEAs 
are mandated for all medicines in a certain category, for 
example, in Italy those with a full innovation status must 
have a national registry that at least determines appropri-
ate use (guiding eligibility for treatment and continuation 
criteria), as was the case for nusinersen, whereas tisagen-
lecleucel was the first product to undergo the “Payment at 
Results” OBMEAs in AIFA. In other countries, the use of 
an OBMEA for nusinersen and tisagenlecleucel was consid-
ered on a case-by-case basis to support appropriate use in 
individual patients and/or data collection to resolve clinical 
(and economic) uncertainties.
The OBMEAs for nusinersen were initiated between 2017 
and 2020 and as shown by Whittal et al. [13] more evidence 
from studies in different sub-populations, clinical study fol-
low-ups and real-world effectiveness might have been avail-
able for the later reimbursement decisions. This could have 
potentially resolved some uncertainties and impacted their 
need for OBMEA. For tisagenlecleucel, decisions were made 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































OBMEA for Nusinersen and Tisagenlecleucel
3.2.2  Form of OBMEAs
In most cases, the purposes of the OBMEAs for nusinersen 
and tisagenlecleucel were clear with specific clinical and/
economic uncertainties named relating to population char-
acteristics, treatment administration, real-life and long-term 
efficacy, expensive concomitant or future treatments, and 
healthcare resource utilisation data. However, the link to 
appraisal reports, which would have been expected to be 
the documented source of the uncertainties, was not always 
clear.
For nusinersen, the individual-based OBMEAs in Table 2 
show that they were generally used to collect outcomes to 
ensure “appropriate use” and determine treatment continu-
ation. The table shows that even for these simpler forms of 
OBMEAs, a range of outcomes needs to be collected.
Only Italy and Spain implemented the more complex 
individual-based OBMEA that used individual outcomes 
to inform a staged payment model for tisagenlecleucel 
(Table 3). The population-based schemes in our case stud-
ies were illuminating because they included many elements 
of the individual-based schemes (with strict appropriateness 
criteria) but they went further to require data aggregation for 
re-analysis at a specific point in the future (Tables 1 and 3).
3.2.3  OBMEA Population and Duration
The reimbursed populations and inclusion criteria for the 
OBMEAs differ somewhat across countries. For nusinersen, 
Belgium simply refers to the regulatory authorised indica-
tion. Others state a variety of exclusion criteria that relate to 
ability to administer treatment (nusinersen), treatment stage 
and potential for response (tisagenlecleucel). These features 
are likely to feature in the clinical judgement of patient suit-
ability in Belgium, even if not explicitly stated.
The differing age (and thus stage) restrictions for nusin-
ersen probably arise from different value judgements made 
by appraisal committees about the extension of evidence 
from small trials in symptomatic young children to pre-
symptomatic children and older patients. Two countries are 
of particular note.
As the indication for reimbursement sought to include all 
sub-types of SMA, this meant that in England, nusinersen 
was evaluated through the NICE Technology Appraisal pro-
gramme. However, if a restriction had been made to type I, it 
would have probably been evaluated through the HST route 
(as was the case for onasemnogene abeparvovec). In the HST 
programme, a different decision-making criteria framework 
is used, including higher willingness-to-pay thresholds. In 
which case, an OBMEA may not have been needed, but 
access would have been restricted to specific patients.
As a pilot in the BENELUXA initiative, Belgium and 
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clinical and cost effectiveness of nusinersen. This informed 
a joint pricing negotiation, but each country implemented 
its own OBMEA as shown in Table 1. In the Netherlands, 
as the assessment report had identified that clinical research 
only included patients aged up to 9.5 years and that evidence 
was not transferable to older patients (SMA types II and 
III), different reimbursement decisions were made for sub-
populations. For those aged 9.5 years and older, a legally 
based OBMEA is ongoing, whereby the health system will 
pay for nusinersen and its administration and the marketing 
authorisation holder must pay the costs of research to col-
lect data to resolve stated uncertainties. For children aged 
under 9.5 years, reimbursement was agreed but, using a 
new arrangement for selected OMPs that seeks to evaluate 
real-life effectiveness and optimise treatment, an informal 
OBMEA (that does not involve the marketing authorisation 
holder) will start in 2021. In contrast, Belgium requested 
data collection on the entire population, but has no mandate 
to ensure these data are collected.
In all countries, treatment and data collection for both 
cases are assigned to a few expert centres that generally 
require some type of authorisation or accreditation. Only 
the Netherlands appears to have provided a sample size esti-
mate for the legal OBMEA. In 2019, estimates were made of 
initially 170 and then 290 patients, with a recruitment period 
of 2 years. In February 2021, 300 patients had been screened 
and two-thirds of those were to be treated with nusinersen. 
For most other countries, the number of patients was explic-
itly named as a key uncertainty and other financial schemes 
were put in place to ensure budget caps.
Several countries have implemented OBMEAs with a 
duration of 2–3 years for these treatments, whereas in Eng-
land, data collection is a minimum of 3 years to enable re-
appraisal within 4.5–5 years or earlier. In the Netherlands, a 
legal OBMEA with nusinersen is planned for 7 years, which 
goes beyond the usual 4-year period permitted, given the 
small number of patients anticipated.
3.2.4  OBMEA Data Collection and Analysis
Most countries are collecting data via a range of approaches 
that depend on each treatment, its uncertainties and the 
existing health data ecosystem infrastructure (clinical and/
or reimbursement or insurance data), with an assumption 
that ongoing clinical studies will be completed. For tisagen-
lecleucel, links have been made to existing chemotherapy 
datasets and national registries for bone marrow transplant, 
whereas for nusinersen links to clinical registries have been 
important or have needed to be established.
Italy and Spain have a national web-based platform for 
which bespoke data collection requirements are created for 
each medicine/therapeutic indication. This not only allows 





















































































































































































































































































































































































































































































































































































































































































































































































































































OBMEA for Nusinersen and Tisagenlecleucel
should encourage timely entry of data to access treatment. 
However, in Italy, the national platform is not linked to the 
hospital reimbursement system and thus duplicate data entry 
is required by the prescribers. In Spain, the platform is being 
established and was not fully functional for tisagenlecleucel.
Costs of OBMEA are unclear, apart from in the well-
established system in Italy, where for an OMP registry the 
marketing authorisation holder pays approximately 30,000 
Euros every three years, with a 10,000 Euros maintenance 
fee from the fourth year. This includes the construct of the 
data collection forms after the pricing and reimbursement 
negotiation, updates on data collection and aggregated 
standard reports.
Only England, the Netherlands and Spain stated an inten-
tion to capture patient-reported outcomes for these cases. 
In England, research was commissioned at the outset of 
the OBMEA for nusinersen to identify existing patient-
reported outcomes that could capture quality-of-life issues 
for patients with SMA. None adequately captured the issues 
that were considered important by patient representatives. 
As a result, the collection of patient-reported outcomes is 
yet to be operationalised. However, this data collection is a 
requirement of the English OBMEA and is expected to form 
part of the evidence submissions at the time of re-appraisal.
In England, the nusinersen OBMEA was undertaken 
within NICE’s HST programme, which requires each 
patient/guardian and their treating physician to sign an 
informed assent form6. These not only provide consent for 
use of data, but also confirm understanding of the OBMEA 
process including the conditions under which treatment 
could be terminated and the implications of withdrawal 
(stopping treatment access).
Detailed data analysis plans were not in place in most 
countries for the nusinersen and tisagenlecleucel OBMEA 
at the outset. Interim data are understandably not intended to 
be published, but some intend to provide updates on progress 
in recruitment in annual reports about OMP use and most 
with CED intend to issue public reports after re-appraisal.
4  Discussion
Outcomes-based managed entry agreements arise from 
appraisal discussions or pricing and reimbursement negotia-
tions to manage outstanding uncertainties (and high prices). 
The Organisation for Economic Co-operation and Develop-
ment report [7] stated that little information is shared or 
published about OBMEAs in terms of treatments involved, 
OBMEA design and results (analyses and decision). This is 
important because OBMEAs require careful governance to 
address data ownership, audit, transparency and appeal [14].
Our research has found information about the purpose, 
duration and data to be collected in the OBMEAs for nusin-
ersen and tisagenlecleucel in several jurisdictions. However, 
this information was only available following close interac-
tion with experts (co-authors of this paper) who knew where 
to find this information on their national websites and who 
could help us translate key information. This has enabled a 
detailed comparison of the constructs of these OBMEA case 
studies, which provides valuable insights that can improve 
future use and implementation of OBMEAs with rare dis-
ease treatments.
Since this research was started, there has been increas-
ing interest in approaches to manage uncertainties with the 
one-off cell and gene therapies, many of which have been 
developed for rare diseases. These therapies rely on benefits 
realisation in the future and thus innovative pricing models 
based on individual outcomes have been used in some cases 
[15–17]. Pricing models have not been the subject of this 
work as issues related to pricing are subject to confidential-
ity agreements. The goal of this work was to identify what 
OBMEA information was available for two specific cases 
and encourage further collaboration to support all jurisdic-
tions and stakeholders in sharing what can easily be made 
public. Work around innovative pricing schemes will clearly 
continue and it will be important to consider it alongside this 
work on OBMEAs.
The nusinersen and tisagenlecleucel case studies demon-
strate that OBMEAs are agreed, at a minimum, in negotia-
tion with the marketing authorisation holder and the payer, 
and for CED in several countries, physicians and research 
groups are involved in the design of data collection. Only 
England and the Netherlands mentioned the involvement of 
patient groups. In the Netherlands, a covenant was signed by 
all stakeholders for the legal OBMEA (CED) of nusinersen. 
This gave written assurance to the Minister of Health that 
the OBMEA would be conducted so that it was capable of 
drawing conclusions about clinical effectiveness at the end 
of the agreement. This purposive approach to data collec-
tion showing the commitment of all stakeholders appears 
to be an important change in the Dutch process to ensure 
the effectiveness of the OBMEA and could be an important 
model for other systems.
Given the investment required from all stakeholders 
in the design and conduct of population-based schemes 
(CED), it is imperative that steps are taken to enable them 
to deliver meaningful results. They should have the rigour 
of a pragmatic trial with clear delineation of uncertainties to 
be resolved (research questions and associated outcomes), 
sample size determination (number of patients and dura-
tion of study), data management processes for data from all 6 https:// www. nice. org. uk/ guida nce/ ta588/ resou rces/ manag ed- access- 
agree ment- july- 2019- pdf- 68428 12573.
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sources and statistical analysis plan. However, these aspects 
were not clear for all the CED examples in our case studies.
4.1  Maximising Data Quantity and Quality
The outcomes studied in the OBMEA case studies to inform 
eligibility, continuation and effectiveness decisions were 
based on measurements used in clinical trials, but not all 
were standard in clinical practice. This adds burdens for 
clinicians, patients and their families. However, in many 
countries, the OBMEA will result in more clinical data than 
was available in the original submission from the market-
ing authorisation holder. Hence, it is important to ensure 
the data, from both individual-based and population-based 
schemes are used not only to optimise care for the patient but 
also to contribute to health system efficiency by determining 
optimal treatment regimes.
Only The Netherlands stipulated a sample size for their 
OBMEA. This demonstrated how sample size considera-
tions for an OBMEA go beyond that for a clinical study 
as the conditional reimbursement implies that all eligible 
patients should have access to treatment. In chronic rare 
diseases, the prevalent population will be eligible for study 
at the outset and those who should recieve treatment first in 
this cohort may need to be prioritised. When all have been 
offered treatment, only newly eligible cases will be avail-
able. When recruitment is complete for the OBMEA, con-
sideration needs to be given as to what happens with other 
eligible patients. For rare diseases, it would seem valuable 
to study these patients and this was recognised in the Neth-
erlands, where an additional study will be established after 
recruitment to the legal OBMEA (not funded by the market-
ing authorisation holder). In England, this is considered on 
a case-by-case basis and for nusinersen those not eligible 
for the OBMEA will form a comparative cohort with risk 
adjustment to allow comparison, if possible.
Although the data to be collected in the OBMEA were 
similar in different countries, the duration of agreements 
differed and the rationale for the duration was unclear. It 
may have been linked to decision-making milestones, such 
as pricing and reimbursement negotiations. Only the Neth-
erlands clearly stated the expected recruitment period and 
duration of follow-up. Such information is important for 
CED and should be clearly documented, taking account of 
the prevalent and incident population in the health juris-
diction  and the timing of the most important outcome 
assessments.
In summer 2020, EUnetHTA Joint Action 3 published 
its first Post-Launch Evidence Generation pilot data col-
lection report for nusinersen [22]. Eight research questions 
addressed uncertainties in SMA sub-populations cover-
ing the number of patients treated, patient characteristics, 
treatment duration, dosing in different patient groups, 
quality-of-life and patient-reported outcomes, long-term 
safety and efficacy, and validation of new outcome measures 
for disease progression effects. A minimum dataset was then 
defined to collect relevant real-world data from nusinersen 
registries in the participating countries (Italy, Croatia, Fin-
land, Norway, Portugal, The Netherlands). Outcomes were 
to be measured at baseline, 6 and 18 months and a brief 
statistical analysis plan was presented. As EUnetHTA Joint 
Action 3 comes to an end in 2021, it is unclear how well this 
study will progress and as can be seen from this case study 
research, countries have initiated their own data collection 
schemes for nusinersen.
Alongside bespoke data collection, marketing authorisa-
tion holders were expected to continue their planned clini-
cal programmes for the case studies, completing ongoing 
studies, and providing longer term follow-up and informa-
tion about various sub-populations. However, none of the 
OBMEAs referred to regulatory post-licensing data require-
ments and how that may bolster evidence in the future and 
be used alongside data arising from the OBMEA.
To maximise information coming from disparate sources, 
linking of records is needed. This can be more easily 
achieved within health systems for secondary use of admin-
istrative data, where consent is presumed in law. However, 
challenges can arise when linkage to other sources, such as 
clinical registries is required. The AIFA registry is a stand-
alone system that does not link to other data, which is seen 
as a limitation by many countries that have good electronic 
health records. For this reason, the new VALTERMED med-
icines’ registry system in Spain is of particular interest, not 
only because of its national status, but because it intends to 
include patient-reported outcomes and to link to other health 
service data.
Several countries are using national registries to collect 
data, SMA disease registries for nusinersen and stem cell 
transplantation registries for tisagenlecleucel. The aim is to 
link to individual patient data and thus national registries are 
preferred. However, as the RWE4Decisions initiative states 
[9], more needs to be done to bring the HTA/payer and clini-
cal communities together to ensure that clinical registries are 
aligned with HTA/payer needs. This needs to include con-
sideration of how the European registries for rare diseases 
being developed by the European Reference Networks can 
be used in jurisdictions.
Our case studies also show that there is opportunity for 
HTA/payers to collaborate across jurisdictions to not only 
align their appraisals to come to a common agreement on 
decision-relevant uncertainties, but to also agree a core data-
set for data collection post-HTA. This could substantially 
improve timeliness and cost and efficiency of data collec-
tion [3] and optimise re-appraisal. However, it is difficult to 
achieve in practice. The BENELUXA joint assessment of 
nusinersen led to agreement on the need for an international 
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SMA registry, but despite this, each country of that partner-
ship developed its own OBMEA as outlined in Tables 1 and 
2. The challenges were also recognised by EUnetHTA who 
stated that for rare diseases “collaboration among Member 
States in the definition of the minimum dataset and in gath-
ering evidence coming from different registries and data-
bases is crucial for HTA” [18].
In the national web-based OBMEA systems, data check-
ing elements are embedded and automatic summary reports 
are produced that update on the level of data collection. 
Where a variety of data sources is used and several treat-
ment centres are involved, careful monitoring processes are 
needed if sufficient data are to be collected, but not all coun-
tries have organised this for the case studies. This is essential 
not only to ensure data quality but to monitor patient recruit-
ment and data completeness of all required assessments. 
NICE uses a multi-stakeholder Managed Access Oversight 
Committee for nusinersen. This committee meets every 6 
months to discuss data collection issues that arise in clinical 
practice and monitors completeness and quality of data. One 
challenging issue that had to be faced in 2020 was the high 
level of missing data as a result of cancelled clinic visits 
because of the COVID-19 pandemic. As a result, alternative 
treatment continuation protocols have been developed and 
data analysis plans modified.
4.2  Capturing Patients’ Perspectives
In the field of rare diseases, knowledge about the disease 
evolves, particularly when the first disease-modifying medi-
cine comes to market in an area of high unmet need. There-
fore, evidence generation post-reimbursement should not 
only seek to resolve uncertainties found in the HTA, but also 
to capture new knowledge about the disease (particularly 
important if comparisons are made to natural history) and 
optimisation of treatment in real life. For this, involvement 
of patients and their informal caregivers would seem essen-
tial. However, there was little evidence of patient involve-
ment in the OBMEA case studies. A few of the OBMEAs 
indicated the plan to collect patient-reported outcomes, 
which are considered particularly important in rare diseases 
[19, 20]. However, there is often no suitable patient-reported 
outcome for a rare disease (as was the case for nusinersen in 
England) and thus other mechanisms are needed to capture 
patients’ perspectives. As part of this project, KF/EK/SU 
have worked with the patient group leaders involved in NICE 
OBMEAs (including for spinal muscular atrophy) to develop 
a patient group submission template for re-appraisal. This 
will enable patient groups to gather evidence from patients 
about the conduct of the OBMEA and the benefits and dis-
benefits of treatment that are not captured in the quantitative 
data collection [21].
4.3  Examples of Successful OBMEA
Coverage with evidence development schemes have been 
criticised for their inability to collect sufficient good quality 
data in a timely manner to inform re-appraisal/pricing and 
reimbursement re-negotiations. As our case studies were 
about the establishment and implementation of OBMEAs, 
not re-appraisal, examples of OBMEAs that had made a dif-
ference were discussed in the expert workshops. Australian 
experts shared examples of OBMEAs for four rare cancers 
and one for lumacaftor/ivacaftor in cystic fibrosis. Of these, 
two are ongoing, one was suspended by the sponsor, one 
led to a change in reimbursement population and one led 
to no change.
In the English Cancer Drugs Fund, brentuximab 
(NICE TA524) and obinutuzumab (NICE TA629) for the 
treatment of rare cancers have completed their OBMEAs 
and resulted in full reimbursement. Elosulfase alfa for muco-
polysaccharidosis type IVA was the first OBMEA enacted 
in the NICE HST programme. The treatment was due to be 
re-appraised in December 2020, but this has been delayed. 
The scope of the re-appraisal was agreed with stakehold-
ers in December 2019. However, in February 2020, the 
re-appraisal was suspended “because the company has not 
provided an evidence submission that is adequate for the 
committee to make a decision and will not accept the terms 
of the charging procedure for HSTs”7. One challenge with 
this re-appraisal is that it will now be undertaken under a 
different decision-making process. Elosulfase alfa (and the 
other early appraisals) did not consider cost effectiveness 
and willingness-to-pay thresholds, but these are now clearly 
stated in their methods8.
Thus, the jury is still out as to whether OBMEA can be 
successful for rare disease treatments, but perhaps through 
greater collaboration among HTA/payers and with stake-
holders, there can be more transparency about uncertain-
ties that exist, constructs for data collection, and sharing 
of results that will optimise treatment and improve health 
service efficiency.
In Italy, where the majority of OBMEAs are individual-
based schemes, changes have related to confidential price 
re-negotiations or optimisation of use, such as alteration 
of continuation criteria. Only a few treatments have been 
withdrawn from reimbursement and this was as a result of 
safety issues raised by regulators9 [11]. Given the increasing 
complexity of treatments coming to market, authors agree 
7 Project information | Elosulfase alfa for treating mucopolysacchari-
dosis type IVa (review of HST2) [ID1643] | Guidance | NICE.
8 https:// www. nice. org. uk/ Media/ Defau lt/ About/ what- we- do/ NICE- 
guida nce/ NICE- highly- speci alised- techn ologi es- guida nce/ HST- inter 
im- metho ds- proce ss- guide- may- 17. pdf.
9 Lartruvo (olaratumab): https:// www. aifa. gov. it/ en/-/ chius ura- regis 
tro- lartr uvo- nota- infor mativa- impor tante.
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there is value in the use of OBMEAs for optimisation of use, 
to perhaps alter the eligible population or criteria for treat-
ment continuation, and to ensure good organisation of care 
such as specialist centre capacity and to monitor the quality 
of care in each centre.
4.4  New National OBMEA Initiatives
In 2019, Germany passed the GSAV law that that gives the 
Federal Joint Committee increased authority to impose data 
collection requirements and price reductions if data do not 
support added value. It is anticipated this will be used for 
OMPs, but no further guidance has been issued. In 2019, 
Scotland also implemented a new “ultra-orphan pathway” 
enabling designated medicines to have an initial HTA review 
by the Scottish Medicines Consortium to identify key uncer-
tainties, then requiring the marketing authorisation holder 
to submit a 3-year data collection plan to the Scottish Gov-
ernment to resolve the uncertainties. Given the small size 
of Scotland, it is likely that the subsequent re-appraisal will 
include data beyond Scotland, but this process is not trans-
parent and few details are available.
5  Conclusions
These case studies show that OBMEAs are being imple-
mented to manage uncertainties relating to the real-life and 
long-term clinical effectiveness and inform economic eval-
uations of rare disease treatments in several jurisdictions. 
This research focuses on understanding how the challenges 
in the establishment and implementation of OBMEAs for 
two different forms of rare disease treatment (nusinersen 
and tisagenlecleucel) have been addressed to deliver data of 
sufficient quantity and quality to inform re-appraisal.
During the IMPACT HTA WP10 research programme, 
a strong message has emerged from all stakeholders that 
OBMEAs should not become routine practice, as their 
implementation is burdensome for all parties. This aligns 
with past research that has queried the sustainability and 
effectiveness of OBMEAs [4] and suggested that OBMEAs 
should be the exception and not the norm. This was strongly 
reiterated by all involved in this case study research.
If OBMEAs are to be a credible conditional reimburse-
ment route for rare disease treatments, the costs and feasibil-
ity of collecting sufficient data to inform decisions must be 
scrutinised at the outset, then steps must be undertaken to 
ensure data quality and completeness. One important mecha-
nism to achieve this could be a covenant agreed by all stake-
holders providing assurance that all necessary actions will 
be taken to ensure that the data collected will be sufficient 
for decision making as implemented in The Netherlands for 
nusinersen.
Bringing together the learnings about establishment of 
OBMEAs for these two case studies of rare disease treat-
ments with previous literature about when to conduct an 
OBMEA, the IMPACT HTA WP10 research team has devel-
oped a checklist to determine the feasibility of undertaking 
an OBMEA for a rare disease treatment [23]. This checklist 
could be used by an individual jurisdiction, or across juris-
dictions, as for some rare diseases (particularly the ultra-
rare), collaborative approaches seem essential. Collaboration 
could foster discussions at the time of appraisal to determine 
decision-relevant uncertainties and a minimum dataset to be 
collected by all and shared in aggregated form for future re-
appraisal. IMPACT HTA WP10 has issued tools to support 
implementation of OBMEA [24, 25] that could help stand-
ardise national approaches and support collaboration, but 
the tools need to be piloted, and adapted with experience.
Another important element to ensuring the efficiency and 
effectiveness of OBMEAs for rare disease treatments is to 
encourage transparency in reporting the plans for, interim 
updates on status and results of OBMEAs. Such information 
should be publicly available and thus perhaps, the HTA data-
base, now hosted by the International Network of Agencies 
for HTA, could be enhanced to host such information. As 
the Organisation for Economic Co-operation and Develop-
ment indicates [7], such sharing could reduce duplication of 
effort across countries and enable learning, which is particu-
larly important for rare disease treatments.
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